The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Viral Vector Purification / Virus Purification Products Market by Vector (AAV, Adenovirus, Lentivirus, Retrovirus and Others), Purification Technique (Chromatography, Centrifugation and Filtration), Therapy (Gene Therapy, Cell Therapy and Viral Vaccines), Therapeutic Area (Oncology, Cardiovascular & Metabolic Disorders, Ophthalmic Disorders, Inflammatory & Immunological Disorders and Others), Scale of Operation (Preclinical / Clinical and Commercial) and Geographical Regions, 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    May 2020

  • Pages
    275

  • View Count
    3340

Example Insights

Viral-Vector-Purification-Virus-Purification-Products-Market-Context Viral-Vector-Purification-Virus-Purification-Products-List-of-products Viral-Vector-Purification-Virus-Purification-Products-Different-types-of-vectors
Viral-Vector-Purification-Virus-Purification-Products-Clinical-trial-analysis Viral-Vector-Purification-Virus-Purification-Products-Developers Viral-Vector-Purification-Virus-Purification-Products-Case-study
Viral-Vector-Purification-Virus-Purification-Products-Global-demand Viral-Vector-Purification-Virus-Purification-Products-Futuer-forecast  

 

Overview

Since the approval and launch of cell and gene therapy products, such as Zolgensma® (2019), ZYNTEGLO™ (2019), Luxturna® (2017), KYMRIAH® (2017) and YESCARTA® (2017), there has been a significant increase in demand for viral vectors. Experts believe that the number of such therapies is likely to double over the next couple of years. It is also worth mentioning that this particular field of medical research received close to USD 10 billion in funding in 2019. Currently, over 1,000 cell and gene therapy-related clinical trials are being conducted, worldwide. Genetic manipulation is a basic requirement of cell and gene therapy development, and, as a result, gene delivery vectors are considered to be of utmost importance in this domain. So far, viral vectors (such as those based on adeno-associated viruses (AAV), adenoviruses, lentivirus, retroviruses and other viruses) have been shown to be the most versatile gene delivery tools available, having demonstrated high transfection efficiencies in both preclinical and clinical settings. Further, taking into account the therapeutic efficacy and low side effects profiles of cell and gene therapies, the demand for such interventions is anticipated to grow at a rapid pace, resulting in a proportional increase in need for appropriate vector systems, as well. However, viral vector development and manufacturing is a complex and cost intensive process. One of the primary concerns associated with viral vector production is related to yield; in fact, a singular batch run is estimated to incur losses of up to 70% during the purification step alone.  

A number of techniques are presently used for viral vector purification. Over the years, size-based viral purification strategies, such as density-gradient ultracentrifugation, ultrafiltration, precipitation and size-exclusion chromatography (SEC), have become part of the accepted industry standard. However, recently, stakeholders have begun relying more on affinity chromatography-based purification regimens, given its robustness and high selectivity. Presently, several companies claim to offer a diverse range of virus purification solutions, including, filter plates, prepacked chromatography columns and resins, and consolidated kits, for viral vector (virus) purification. As indicated earlier, downstream processing of viral vector products is challenging. Existing separation and purification techniques are not efficient when it comes to purifying viral vectors at large scales. Moreover, these techniques are often unable to separate complete viruses from empty capsids, thereby, compromising product recovery. Therefore, it has become essential for stakeholders to develop innovative ways to optimize the purification process, in order to further improve virus recovery and facilitate effective removal of contaminants / impurities. Currently, the viral vector purification products market is driven by abovementioned surge in demand for viral vectors. In this context, it is worth mentioning that there are several virus based vaccines under development against the novel SARS-CoV-2 coronavirus strain. In fact, according to the WHO, there are over 20 viral vaccines currently being investigated against the novel coronavirus. Developing the means to better purify viruses is, therefore, likely to significantly impact viable vaccine yield. The current crisis is definitely going to have a strong impact on the virus purification products market.

Scope of the Report

The ‘Viral Vector Purification  / Virus Purification Products Market (kit, prepacked column, resin, cassette, filter plate, capsule, reagent and others), 2020-2030’ report features an extensive study of various products available for viral vector purification, in addition to the current market landscape and future potential of product developers. Amongst other elements, the report features: 

  • An overview of the current market landscape of companies providing products for purification of viruses / viral vectors, using different techniques, such as chromatography, centrifugation and filtration. It features information on the type of product (kit, prepacked column, resin, cassette, filter plate, capsule and reagent), type of purification technique (chromatography, centrifugation and filtration),  scale of operation (lab-scale, clinical and commercial), type of viral vector (AAV, adenovirus, lentivirus, retrovirus and others) and details on other physical and operational parameters of the product (such as matrix, pore size, volume of bed, flow rate, operating pressure, working temperature, pH, filtration area and process time). In addition, the chapter includes information on the purification product developers, including details on the year of establishment, company size and location of headquarters.
  • Elaborate profiles of key players, including an overview of the company, product portfolio (viral vector purification products), recent developments and an informed future outlook.  
  • An analysis evaluating the potential strategic partners (comprising of viral vector-based therapy developers and viral vector manufacturers) for viral vector purification product developers, based on several parameters, such as type of viral vector,  developer strength, operational strength, therapeutic area, strength of clinical pipeline and strength of preclinical pipeline.
  • A clinical trial analysis of completed, ongoing and planned studies of various viral vector-based cell therapies, gene therapies and vaccines (approved / under development). It features detailed analyses of clinical studies of different viral-vector based therapies on the basis of their registration year, phase of development, trial status, type of therapy, therapeutic area, type of sponsor / collaborator, geographical location, number of patients enrolled and key players. 
  • An informed estimate of the annual clinical and commercial demand (in terms of number of patients) for viral vectors, taking into account the marketed gene-based therapies and clinical studies evaluating vector-based therapies; the analysis also takes into consideration various relevant parameters, such as target patient population, dosing frequency and dose strength. Further, the demand has been segregated on the basis of type of viral vector, type of therapy, therapeutic are and geographical location. 
  • A case study on tangential flow filtration (TFF), highlighting the role, advantages and disadvantages of the technique for purification of viral vectors; the chapter features details of products used for TFF, including product type, scale of operation, membrane material, flow rate and filtration area.
  • A case study featuring the viral vector manufacturers providing commercial scale production, highlighting details on their year of establishment, company size, type of viral vector (AAV, adenovirus, lentivirus, retrovirus and others), purpose of production (in-house and contract-basis), and location of headquarters and manufacturing facilities. 

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for viral vector purification product developers, over the coming decade. Based on various parameters, such as the likely increase in number of clinical studies related to viral vector-based therapies, anticipated growth in target patient population, existing price variations across different purification techniques, and the success of cell and gene therapy products (considering both approved and late-stage clinical candidates), we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] type of viral vector (AAV, adenovirus, lentivirus, retrovirus and others), [B] type of purification technique (chromatography, centrifugation and filtration), [C] type of therapy (gene therapy, cell therapy and viral vaccines) [D] therapeutic area (oncological disorders, cardiovascular disorders, ophthalmic disorders, metabolic disorders, inflammation & immunological diseases and others), [E] scale of operation (preclinical / clinical and commercial) and [F] key geographical regions (North America, Europe, Asia Pacific and rest of the world). 

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. The opinions and insights presented in the report were influenced by discussions held with several players in this industry. The study includes detailed transcripts of discussions held with the following individuals: 

  • Haifeng Chen (Chief Executive Officer, Virovek)
  • Jeffrey Hung (Chief Commercial Officer, Vigene Biosciences)
  • Kai Lipinski (Chief Scientific Officer, Vibalogics)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the viral vector purification product in the short to mid-term, and long term.

Chapter 3 provides a general overview of various types of viral and non-viral vectors. It includes a detailed discussion on the methods of gene transfer, type of viral vectors and applications of viral vectors in various advanced therapies. It provides information on the different stages of the viral vector purification process, type of purification techniques used and the key challenges associated with the purification of viral vectors. Further, it includes a review of the latest trends and innovations in the vector purification market.

Chapter 4 is an overview of the various types of products used for purification techniques based on principles of chromatography, centrifugation and filtration. It highlights product specific information, such as type of product (kit, prepacked column, resin, cassette, filter plate, capsule and reagent),  type of purification technique (chromatography, centrifugation and filtration), scale of operation (lab-scale, clinical and commercial), type of viral vector (adenovirus, AAV, lentivirus, retrovirus and others), type of chromatographic technique (affinity chromatography, ion-exchange chromatography, size-exclusion chromatography and hydrophilic interaction chromatography), pack size (wherever specified) and price (wherever specified). In addition, the chapter provides details on certain additional parameters (based on the purification technique, wherever applicable), such as type of matrix, binding capacity, particle size, volume of bed, flow rate, operating pressure, working temperature, process time and pH. The chapter also provides information on the purification product developers, including year of establishment, company size and location of headquarters. 

Chapter 5 includes detailed profiles of players offering  products for viral vector purification. Each profile features an overview of the company, , information on its product portfolio, recent developments and an informed future outlook.

Chapter 6 highlights potential strategic partners (comprising of viral vector-based therapy developers and viral vector manufacturers) for viral vector purification product developers, based on multiple parameters, such as type of viral vector, developer strength, operational strength, therapeutic areas, strength of clinical pipeline and strength of preclinical pipeline. The analysis aims to provide the necessary inputs to the product developers, enabling them to make the right decisions to collaborate with industry stakeholders with relatively more initiatives in the domain.

Chapter 7 features a geographical clinical trial analysis of completed, ongoing and planned studies of viral vector-based cell therapies, gene therapies and vaccines (approved / under development). The analysis provides details related to the different types of viral vectors investigated / being investigated across various geographies, based on the number of clinical trials, registration year, phase of development, trial status, type of therapy, therapeutic area, type of sponsor / collaborator, number of patients enrolled, key players and type of viral vector.

Chapter 8 features an informed estimate of the annual demand for viral vectors, taking into account the viral vector based marketed therapies and clinical studies. For the purpose of estimating the current clinical demand, we considered the active clinical studies of different types of vector-based therapies that have been registered till date. The data was analyzed on the basis of various parameters, such as number of annual clinical doses, trial location, and the enrolled patient population across different geographies. Further, in order to estimate the commercial demand, we considered the marketed vector-based therapies, based on various parameters, such as target patient population, dosing frequency and dose strength. The chapter features analyses demand on the basis of type of viral vector, type of therapy, therapeutic are and geographical location.

Chapter 9 is a detailed case study which provides an overview of the tangential flow filtration, highlighting its role, advantages and disadvantages. It features key details of the products used for tangential flow filtration, such as type of product, scale of operation, membrane material, flow rate and filtration area. 

Chapter 10 is a detailed case study which provides an overview of the viral vector manufacturers. It features an in-depth analysis of the commercial scale viral vector manufacturers, highlighting details on their year of establishment, company size, types of vectors (AAV, adenovirus, lentivirus, retrovirus and others), purpose of production (in-house and contract-basis), headquarters and manufacturing facilities. 

Chapter 11 presents an insightful market forecast analysis, highlighting the future potential of the virus purification products market till the year 2030. We have segregated the opportunity of the market on the basis of [A] type of viral vector (AAV, adenovirus, lentivirus, retrovirus and others), [B] type of purification technique (chromatography, centrifugation and filtration), [C] type of therapy (gene therapy, cell therapy and viral vaccines) [D] therapeutic area (oncological disorders, cardiovascular disorders, ophthalmic disorders, metabolic disorders, inflammation & immunological diseases and others), [E] scale of operation (preclinical / clinical and commercial) and [F] geographical location (North America, Europe, Asia Pacific and rest of the world).

Chapter 12 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 13 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with (in alphabetical order) Haifeng Chen (Chief Executive Officer, Virovek), Jeffrey Hung (Chief Commercial Officer, Vigene Biosciences) and Kai Lipinski (Chief Scientific Officer, Vibalogics).

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 15 is an appendix, which provides a list of companies and organizations mentioned in this report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Viral and Non-Viral Methods of Gene Transfer
3.3. Viral Vectors for Genetically Modified Therapies
3.4. Types of Viral Vectors
3.4.1. Adeno-associated Viral Vectors

3.4.2. Adenoviral Vectors
3.4.3. Lentiviral Vectors
3.4.4. Retroviral Vectors
3.4.5. Other Viral Vectors
3.4.5.1. Alphavirus
3.4.5.2. Foamy Virus
3.4.5.3. Herpes Simplex Virus
3.4.5.4. Sendai Virus
3.4.5.5. Simian Virus
3.4.5.6. Vaccinia Virus

3.6. Applications of Viral Vectors
3.6.1. Cell and Gene Therapy
3.6.1. Vaccinology

3.7. Current Trends in Vector Development / Manufacturing
3.7.1. Vector Engineering
3.7.2. Cargo Engineering

3.8. Vector Manufacturing
3.8.1. Types of Vector Manufacturers
3.8.2. Viral Vector Manufacturing Process
3.8.3. Challenges Related to Vector Manufacturing
3.8.3.1. Vector Purification Process
3.8.3.2. Techniques Used for Vector Purification
3.8.3.2.1. Centrifugation and Ultra-Centrifugation
3.8.3.2.2. Filtration
3.8.3.2.3. Chromatography
3.8.3.3. Challenges Related to Vector Purification

3.9. Future of Vector Purification

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Viral Vector Purification Products: Overall Market Landscape
4.2.1. Analysis by Type of Product
4.2.2. Analysis by Type of Purification Technique
4.2.3. Analysis by Scale of Operation
4.2.5. Analysis by Type of Viral Vector
4.2.6. Viral Vector Purification Products for Chromatography
4.2.6.1. Analysis by Type of Chromatographic Technique
4.2.7. Viral Vector Purification Products for Centrifugation
4.2.8. Viral Vector Purification Products for Filtration

4.3. Viral Vector Purification Product Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Geographical Location

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Agilent Technologies
5.2.1. Company Overview
5.2.2. Product Portfolio
5.2.3. Recent Developments and Future Outlook

5.3. BIA Separations
5.3.1. Company Overview
5.3.2. Product Portfolio
5.3.3. Recent Developments and Future Outlook

5.4. Bio-Rad Laboratories
5.4.1. Company Overview
5.4.2. Product Portfolio
5.4.3. Recent Developments and Future Outlook

5.5. BioVision
5.5.1. Company Overview
5.5.2. Product Portfolio
5.5.3. Recent Developments and Future Outlook

5.6. Cytiva (formerly GE Lifesciences)
5.6.1. Company Overview
5.6.2. Product Portfolio
5.6.3. Recent Developments and Future Outlook

5.7. Merck
5.7.1. Company Overview
5.7.2. Product Portfolio
5.7.3. Recent Developments and Future Outlook

5.8. Sartorius
5.8.1. Company Overview
5.8.2. Product Portfolio
5.8.3. Recent Developments and Future Outlook

5.9. Takara Bio
5.9.1. Company Overview
5.9.2. Product Portfolio
5.9.3. Recent Developments and Future Outlook

5.10. Thermo Fisher Scientific
5.10.1. Company Overview
5.10.2. Product Portfolio
5.10.3. Recent Developments and Future Outlook

6. STRATEGIC PARTNER ANALYSIS
6.1. Chapter Overview
6.2. Methodology and Key Parameters
6.3. Potential Strategic Partners: Viral Vector-based Therapy Developers
6.3.1. Strategic Partner Analysis: AAV Vector-based Therapy Developers
6.3.1.1. Most Likely Partners
6.3.1.2. Likely Partners
6.3.1.3. Less Likely Partners
6.3.1.4. Least Likely Partners

6.3.2. Strategic Partner Analysis: Adenoviral Vector-based Therapy Developers
6.3.2.1. Most Likely Partners
6.3.2.2. Likely Partners
6.3.2.3. Less Likely Partners
6.3.2.4. Least Likely Partners

6.3.3. Strategic Partner Analysis: Lentiviral Vector-based Therapy Developers
6.3.3.1. Most Likely Partners
6.3.3.2. Likely Partners
6.3.3.3. Less Likely Partners
6.3.3.4. Least Likely Partners

6.3.4. Strategic Partner Analysis: Retroviral Vector-based Therapy Developers
6.3.4.1. Most Likely Partners
6.3.4.2. Likely Partners
6.3.4.3. Less Likely Partners
6.3.4.4. Least Likely Partners

6.3.5. Strategic Partner Analysis: Other Viral Vector-based Therapy Developers
6.3.5.1. Most Likely Partners
6.3.5.2. Likely Partners
6.3.5.3. Less Likely Partners
6.3.5.4. Least Likely Partners

6.4. Potential Strategic Partners: Viral Vector Manufacturers
6.4.1. Strategic Partner Analysis: AAV Vector Manufacturers
6.4.1.1. Most Likely Partners
6.4.1.2. Likely Partners
6.4.1.3. Less Likely Partners
6.4.1.4. Least Likely Partners

6.4.2. Strategic Partner Analysis: Adenoviral Vector Manufacturers
6.4.2.1. Most Likely Partners
6.4.2.2. Likely Partners
6.4.2.3. Less Likely Partners
6.4.2.4. Least Likely Partners

6.4.3. Strategic Partner Analysis: Lentiviral Vector Manufacturers
6.4.3.1. Most Likely Partners
6.4.3.2. Likely Partners
6.4.3.3. Less Likely Partners
6.4.3.4. Least Likely Partners

6.4.4. Strategic Partner Analysis: Retroviral Vector Manufacturers
6.4.4.1. Most Likely Partners
6.4.4.2. Likely Partners
6.4.4.3. Less Likely Partners
6.4.4.4. Least Likely Partners

6.4.5. Strategic Partner Analysis: Other Viral Vector Manufacturers
6.4.5.1. Most Likely Partners
6.4.5.2. Likely Partners
6.4.5.3. Less Likely Partners
6.4.5.4. Least Likely Partners

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Viral Vector based Therapies: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Phase
7.3.3. Analysis by Trial Status
7.3.4. Analysis by Type of Therapy
7.3.5. Analysis by Therapeutic Area
7.3.6. Analysis by Type of Sponsor / Collaborator
7.3.7. Analysis by Geographical Location and Trial Status
7.3.8. Most Active Players: Analysis by Number of Registered Trials
7.3.9. Analysis by Patients Enrolled and Trial Phase
7.3.10. Analysis by Patients Enrolled and Type of Therapy
7.3.11. Analysis by Patients Enrolled and Therapeutic Area
7.3.12. Analysis by Patients Enrolled, Trial Status and Geographical Location

7.4. AAV Vector based Therapies
7.4.1. Analysis by Trial Registration Year
7.4.2. Analysis by Trial Phase
7.4.3. Analysis by Trial Status
7.4.4. Analysis by Type of Therapy
7.4.5. Analysis by Therapeutic Area
7.4.6. Analysis by Type of Sponsor / Collaborator
7.4.7. Analysis by Geographical Location and Trial Status
7.4.8. Most Active Players: Analysis by Number of Registered Trials
7.4.9. Analysis by Patients Enrolled and Trial Phase
7.4.10. Analysis by Patients Enrolled and Type of Therapy
7.4.11. Analysis by Patients Enrolled and Therapeutic Area
7.4.12. Analysis by Patients Enrolled, Trial Status and Geographical Location

7.5. Adenoviral Vector based Therapies
7.5.1. Analysis by Trial Registration Year
7.5.2. Analysis by Trial Phase
7.5.3. Analysis by Trial Status
7.5.4. Analysis by Type of Therapy
7.5.5. Analysis by Therapeutic Area
7.5.6. Analysis by Type of Sponsor / Collaborator
7.5.7. Analysis by Geographical Location and Trial Status
7.5.8. Most Active Players: Analysis by Number of Registered Trials
7.5.9. Analysis by Patients Enrolled and Trial Phase
7.5.10. Analysis by Patients Enrolled and Type of Therapy
7.5.11. Analysis by Patients Enrolled and Therapeutic Area
7.5.12. Analysis by Patients Enrolled, Trial Status and Geographical Location

7.6. Lentiviral Vector based Therapies
7.6.1. Analysis by Trial Registration Year
7.6.2. Analysis by Trial Phase
7.6.3. Analysis by Trial Status
7.6.4. Analysis by Type of Therapy
7.6.5. Analysis by Therapeutic Area
7.6.6. Analysis by Type of Sponsor / Collaborator
7.6.7. Analysis by Geographical Location and Trial Status
7.6.8. Most Active Players: Analysis by Number of Registered Trials
7.6.9. Analysis by Patients Enrolled and Trial Phase
7.6.10. Analysis by Patients Enrolled and Type of Therapy
7.6.11. Analysis by Patients Enrolled and Therapeutic Area
7.6.12. Analysis by Patients Enrolled, Trial Status and Geographical Location

7.7. Retroviral Vector based Therapies
7.7.1. Analysis by Trial Registration Year
7.7.2. Analysis by Trial Phase
7.7.3. Analysis by Trial Status
7.7.4. Analysis by Type of Therapy
7.7.5. Analysis by Therapeutic Area
7.7.6. Analysis by Type of Sponsor / Collaborator
7.7.7. Analysis by Geographical Location and Trial Status
7.7.8. Most Active Players: Analysis by Number of Registered Trials
7.7.9. Analysis by Patients Enrolled and Trial Phase
7.7.10. Analysis by Patients Enrolled and Type of Therapy
7.7.11. Analysis by Patients Enrolled and Therapeutic Area
7.7.12. Analysis by Patients Enrolled, Trial Status and Geographical Location

7.8. Other Viral Vector based Therapies
7.8.1. Analysis by Trial Registration Year
7.8.2. Analysis by Trial Phase
7.8.3. Analysis by Trial Status
7.8.4. Analysis by Type of Therapy
7.8.5. Analysis by Therapeutic Area
7.8.6. Analysis by Type of Sponsor / Collaborator
7.8.7. Analysis by Geographical Location and Trial Status
7.8.8. Most Active Players: Analysis by Number of Registered Trials
7.8.9. Analysis by Patients Enrolled and Trial Phase
7.8.10. Analysis by Patients Enrolled and Type of Therapy
7.8.11. Analysis by Patients Enrolled and Therapeutic Area
7.8.12. Analysis by Patients Enrolled, Trial Status and Geographical Location

8. DEMAND ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Methodology

8.3. Global, Clinical Demand for Viral Vectors
8.3.1. Analysis by Type of Vector
8.3.2. Analysis by Type of Therapy
8.3.3. Analysis by Therapeutic Area
8.3.4. Analysis by Geographical Location

8.4. Global, Commercial Demand for Viral Vectors
8.4.1. Analysis by Type of Vector
8.4.2. Analysis by Type of Therapy
8.4.3. Analysis by Therapeutic Area
8.4.4. Analysis by Geographical Location

9. CASE STUDY: TANGENTIAL FLOW FILTRATION (TFF)
9.1. Chapter Overview
9.2. Role of TFF in Viral Vector Purification
9.2.1. Advantages of TFF
9.2.2. Disadvantages of TFF
9.3. TFF-related Product Suppliers

10. CASE STUDY: VIRAL VECTOR MANUFACTURERS
10.1. Chapter Overview
10.2. Commercial Scale Viral Vector Manufacturers
10.2.1. Analysis by Year of Establishment
10.2.2. Analysis by Company Size
10.2.3. Analysis by Type of Viral Vector
10.2.4. Analysis by Purpose of Production
10.2.5. Analysis by Geographical Location

11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Overall Viral Vector Purification Products Market, 2020-2030
11.3.1. Viral Vector Purification Products Market: Distribution by Type of Viral Vector, 2020-2030
11.3.2. Viral Vector Purification Products Market: Distribution by Type of Purification Technique, 2020-2030
11.3.3. Viral Vector Purification Products Market: Distribution by Type of Therapy, 2020-2030
11.3.4. Viral Vector Purification Products Market: Distribution by Therapeutic Area, 2020-2030
11.3.5. Viral Vector Purification Products Market: Distribution by Scale of Operation, 2020-2030
11.3.6. Viral Vector Purification Products Market: Distribution by Geographical Location, 2020-2030

11.4. Viral Vector Purification Products Market for AAV Vectors, 2020-2030
11.4.1. AAV Vector Purification Products Market: Distribution by Type of Purification Technique, 2020-2030
11.4.2. AAV Vector Purification Products Market: Distribution by Type of Therapy, 2020-2030
11.4.3. AAV Vector Purification Products Market: Distribution by Therapeutic Area, 2020-2030
11.4.4. AAV Vector Purification Products Market: Distribution by Scale of Operation, 2020-2030
11.4.5. AAV Vector Purification Products Market: Distribution by Geographical Location, 2020-2030

11.5. Viral Vector Purification Products Market for Adenoviral Vectors, 2020-2030
11.5.1. Adenoviral Vector Purification Products Market: Distribution by Type of Purification Technique, 2020-2030
11.5.2. Adenoviral Vector Purification Products Market: Distribution by Type of Therapy, 2020-2030
11.5.3. Adenoviral Vector Purification Products Market: Distribution by Therapeutic Area, 2020-2030
11.5.4. Adenoviral Vector Purification Products Market: Distribution by Scale of Operation, 2020-2030
11.5.5. Adenoviral Vector Purification Products Market: Distribution by Geographical Location, 2020-2030

11.6. Viral Vector Purification Products Market for Lentiviral Vectors, 2020-2030
11.6.1. Lentiviral Vector Purification Products Market: Distribution by Type of Purification Technique, 2020-2030
11.6.2. Lentiviral Vector Purification Products Market: Distribution by Type of Therapy, 2020-2030
11.6.3. Lentiviral Vector Purification Products Market: Distribution by Therapeutic Area, 2020-2030
11.6.4. Lentiviral Vector Purification Products Market: Distribution by Scale of Operation, 2020-2030
11.6.5. Lentiviral Vector Purification Products Market: Distribution by Geographical Location, 2020-2030

11.7. Viral Vector Purification Products Market for Retroviral Vectors, 2020-2030
11.7.1. Retroviral Vector Purification Products Market: Distribution by Type of Purification Technique, 2020-2030
11.7.2. Retroviral Vector Purification Products Market: Distribution by Type of Therapy, 2020-2030
11.7.3. Retroviral Vector Purification Products Market: Distribution by Therapeutic Area, 2020-2030
11.7.4. Retroviral Vector Purification Products Market: Distribution by Scale of Operation, 2020-2030
11.7.5. Retroviral Vector Purification Products Market: Distribution by Geographical Location, 2020-2030

11.8. Viral Vector Purification Products Market for Other Viral Vectors, 2020-2030
11.8.1. Other Viral Vector Purification Products Market: Distribution by Type of Purification Technique, 2020-2030
11.8.2. Other Viral Vector Purification Products Market: Distribution by Type of Therapy, 2020-2030
11.8.3. Other Viral Vector Purification Products Market: Distribution by Therapeutic Area, 2020-2030
11.8.4. Other Viral Vector Purification Products Market: Distribution by Scale of Operation, 2020-2030
11.8.5. Other Viral Vector Purification Products Market: Distribution by Geographical Location, 2020-2030

12. CONCLUDING REMARKS

13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. Virovek
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Haifeng Chen, Chief Executive Officer

13.3. Vigene Biosciences
13.3.1. Company Snapshot
13.3.2. Interview Transcript: Jeffrey Hung, Chief Commercial Officer

13.4. Vibalogics
13.4.1. Company Snapshot
13.4.2. Interview Transcript: Kai Lipinski, Chief Scientific Officer

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Gene Transfer: Viral and Non-Viral Methods
Figure 3.2 Vector Manufacturing: Different Types of Manufacturers
Figure 3.3 Vector Manufacturing: Process Steps
Figure 4.1 Viral Vector Purification Products: Distribution by Type of Product
Figure 4.2 Viral Vector Purification Products: Distribution by Type of Purification Technique
Figure 4.3 Viral Vector Purification Products: Distribution by Scale of Operation
Figure 4.4 Viral Vector Purification Products: Distribution by Type of Viral Vector
Figure 4.5 Viral Vector Purification Products: Distribution by Type of Chromatographic Technique
Figure 4.6 Viral Vector Purification Product Developers: Distribution by Year of Establishment
Figure 4.7 Viral Vector Purification Product Developers: Distribution by Company Size
Figure 4.8 Viral Vector Purification Product Developers: Distribution by Geographical Location
Figure 7.1 Viral Vector based Therapies: Distribution by Trial Registration Year
Figure 7.2 Viral Vector-based Therapies: Distribution by Trial Phase
Figure 7.3 Viral Vector-based Therapies: Distribution by Trial Status
Figure 7.4 Viral Vector-based Therapies: Distribution by Type of Therapy
Figure 7.5 Viral Vector-based Therapies: Distribution by Therapeutic Area
Figure 7.6 Viral Vector-based Therapies: Distribution by Type of Sponsor / Collaborator
Figure 7.7 Viral Vector-based Therapies: Distribution by Geographical Location and Trial Status
Figure 7.8 Viral Vector based Therapies: Most Active Players by Number of Registered Trials
Figure 7.9 Viral Vector-based Therapies: Distribution by Patients Enrolled and Trial Phase
Figure 7.10 Viral Vector-based Therapies: Distribution by Patients Enrolled and Type of Therapy
Figure 7.11 Viral Vector-based Therapies: Distribution by Patients Enrolled and Therapeutic Area
Figure 7.12 Viral Vector-based Therapies: Distribution by Patients Enrolled, Trial Status and Geographical Location
Figure 7.13 AAV Vector-based Therapies: Distribution by Trial Registration Year
Figure 7.14 AAV Vector-based Therapies: Distribution by Trial Phase
Figure 7.15 AAV Vector-based Therapies: Distribution by Trial Status
Figure 7.16 AAV Vector-based Therapies: Distribution by Type of Therapy
Figure 7.17 AAV Vector-based Therapies: Distribution by Therapeutic Area
Figure 7.18 AAV Vector-based Therapies: Distribution by Type of Sponsor / Collaborator
Figure 7.19 AAV Vector--based Therapies: Distribution by Geographical Location and Trial Status
Figure 7.20 AAV Vector-based Therapies: Most Active Players by Number of Registered Trials
Figure 7.21 AAV Vector-based Therapies: Distribution by Patients Enrolled and Trial Phase
Figure 7.22 AAV Vector-based Therapies: Distribution by Patients Enrolled and Type of Therapy
Figure 7.23 AAV Vector-based Therapies: Distribution by Patients Enrolled and Therapeutic Area
Figure 7.24 AAV Vector-based Therapies: Distribution by Patients Enrolled, Trial Status and Geographical Location
Figure 7.25 Adenoviral Vector-based Therapies: Distribution by Trial Registration Year
Figure 7.26 Adenoviral Vector-based Therapies: Distribution by Trial Phase
Figure 7.27 Adenoviral Vector-based Therapies: Distribution by Trial Status
Figure 7.28 Adenoviral Vector-based Therapies: Distribution by Type of Therapy
Figure 7.29 Adenoviral Vector-based Therapies: Distribution by Therapeutic Area
Figure 7.30 Adenoviral Vector-based Therapies: Distribution by Type of Sponsor / Collaborator
Figure 7.31 Adenoviral Vector-based Therapies: Distribution by Geographical Location and Trial Status
Figure 7.32 Adenoviral Vector-based Therapies: Most Active Players by Number of Registered Trials
Figure 7.33 Adenoviral Vector-based Therapies: Distribution by Patients Enrolled and Trial Phase
Figure 7.34 Adenoviral Vector-based Therapies: Distribution by Patients Enrolled and Type of Therapy
Figure 7.35 Adenoviral Vector-based Therapies: Distribution by Patients Enrolled and Therapeutic Area
Figure 7.36 Adenoviral Vector-based Therapies: Distribution by Patients Enrolled, Trial Status and Geographical Location
Figure 7.37 Lentiviral Vector-based Therapies: Distribution by Trial Registration Year
Figure 7.38 Lentiviral Vector-based Therapies: Distribution by Trial Phase
Figure 7.39 Lentiviral Vector-based Therapies: Distribution by Trial Status
Figure 7.40 Lentiviral Vector-based Therapies: Distribution by Type of Therapy
Figure 7.41 Lentiviral Vector-based Therapies: Distribution by Therapeutic Area
Figure 7.42 Lentiviral Vector-based Therapies: Distribution by Type of Sponsor / Collaborator
Figure 7.43 Lentiviral Vector-based Therapies: Distribution by Geographical Location
Figure 7.44 Lentiviral Vector-based Therapies: Most Active Players by Number of Registered Trials
Figure 7.45 Lentiviral Vector-based Therapies: Distribution by Patients Enrolled and Trial Phase
Figure 7.46 Lentiviral Vector-based Therapies: Distribution by Patients Enrolled and Type of Therapy
Figure 7.47 Lentiviral Vector-based Therapies: Distribution by Patients Enrolled and Therapeutic Area
Figure 7.48 Lentiviral Vector-based Therapies: Distribution by Patients Enrolled, Trial Status and Geographical Location
Figure 7.49 Retroviral Vector-based Therapies: Distribution by Trial Registration Year
Figure 7.50 Retroviral Vector-based Therapies: Distribution by Trial Phase
Figure 7.51 Retroviral Vector-based Therapies: Distribution by Trial Status
Figure 7.52 Retroviral Vector-based Therapies: Distribution by Type of Therapy
Figure 7.53 Retroviral Vector-based Therapies: Distribution by Therapeutic Area
Figure 7.54 Retroviral Vector-based Therapies: Distribution by Type of Sponsor / Collaborator
Figure 7.55 Retroviral Vector-based Therapies: Distribution by Geographical Location
Figure 7.56 Retroviral Vector-based Therapies: Most Active Players by Number of Registered Trials
Figure 7.57 Retroviral Vector-based Therapies: Distribution by Patients Enrolled and Trial Phase
Figure 7.58 Retroviral Vector-based Therapies: Distribution by Patients Enrolled and Type of Therapy
Figure 7.59 Retroviral Vector-based Therapies: Distribution by Patients Enrolled and Therapeutic Area
Figure 7.60 Retroviral Vector-based Therapies: Distribution by Patients Enrolled, Trial Status and Geographical Location
Figure 7.61 Other Viral Vector-based Therapies: Distribution by Trial Registration Year
Figure 7.62 Other Viral Vector-based Therapies: Distribution by Trial Phase
Figure 7.63 Other Viral Vector-based Therapies: Distribution by Trial Status
Figure 7.64 Other Viral Vector-based Therapies: Distribution by Type of Therapy
Figure 7.65 Other Viral Vector-based Therapies: Distribution by Therapeutic Area
Figure 7.66 Other Viral Vector-based Therapies: Distribution by Type of Sponsor / Collaborator
Figure 7.67 Other Viral Vector-based Therapies: Distribution by Geographical Location
Figure 7.68 Other Viral Vector-based Therapies: Most Active Players by Number of Registered Trials
Figure 7.69 Other Viral Vector-based Therapies: Distribution by Patients Enrolled and Trial Phase
Figure 7.70 Other Viral Vector-based Therapies: Distribution by Patients Enrolled and Type of Therapy
Figure 7.71 Other Viral Vector-based Therapies: Distribution by Patients Enrolled and Therapeutic Area
Figure 7.72 Other Viral Vector-based Therapies: Distribution by Patients Enrolled, Trial Status and Geographical Location
Figure 8.1. Global Clinical Demand for Viral Vectors, 2020-2030 (Thousand Patients)
Figure 8.2. Clinical Demand for Viral Vectors: Distribution by Type of Vector (Thousand Patients)
Figure 8.3. Clinical Demand for Viral Vectors: Distribution by Type of Therapy (Thousand Patients)
Figure 8.4. Clinical Demand for Viral Vectors: Distribution by Therapeutic Area (Thousand Patients)
Figure 8.5. Clinical Demand for Viral Vectors: Distribution by Geographical Location (Thousand Patients)
Figure 8.6. Global Commercial Demand for Viral Vectors, 2020-2030 (Thousand Patients)
Figure 8.7. Commercial Demand for Viral Vectors: Distribution by Type of Vector (Thousand Patients)
Figure 8.8. Commercial Demand for Viral Vectors: Distribution by Type of Therapy (Thousand Patients)
Figure 8.9. Commercial Demand for Viral Vectors: Distribution by Therapeutic Area (Thousand Patients)
Figure 8.10. Commercial Demand for Viral Vectors: Distribution by Geographical Location (Thousand Patients)
Figure 10.1 Commercial Scale Viral Vector Manufacturers: Distribution by Year of Establishment
Figure 10.2 Commercial Scale Viral Vector Manufacturers: Distribution by Company Size
Figure 10.3 Commercial Scale Viral Vector Manufacturers: Distribution by Type of Viral Vector
Figure 10.4 Commercial Scale Viral Vector Manufacturers: Distribution by Purpose of Production
Figure 10.5 Commercial Scale Viral Vector Manufacturers: Distribution by Geographical Location
Figure 11.1 Overall Viral Vector Purification Products Market, 2020-2030 (USD Million)
Figure 11.2 Viral Vector Purification Products Market: Distribution by Type of Viral Vector, 2020-2030 (USD Million)
Figure 11.3 Viral Vector Purification Products Market: Distribution by Type of Purification Technique, 2020-2030 (USD Million)
Figure 11.4 Viral Vector Purification Products Market: Distribution by Type of Therapy, 2020-2030 (USD Million)
Figure 11.5 Viral Vector Purification Products Market: Distribution by Therapeutic Area, 2020-2030 (USD Million)
Figure 11.6 Viral Vector Purification Products Market: Distribution by Scale of Operation, 2020-2030 (USD Million)
Figure 11.7 Viral Vector Purification Products Market: Distribution by Geographical Location, 2020-2030 (USD Million)
Figure 11.8 Viral Vector Purification Products Market for AAV Vectors, 2020-2030 (USD Million)
Figure 11.9 AAV Vector Purification Products Market: Distribution by Type of Purification Technique, 2020-2030 (USD Million)
Figure 11.10 AAV Vector Purification Products Market: Distribution by Type of Therapy, 2020-2030 (USD Million)
Figure 11.11 AAV Vector Purification Products Market: Distribution by Therapeutic Area, 2020-2030 (USD Million)
Figure 11.12 AAV Vector Purification Products Market: Distribution by Scale of Operation, 2020-2030 (USD Million)
Figure 11.13 AAV Vector Purification Products Market: Distribution by Geographical Location, 2020-2030 (USD Million)
Figure 11.14 Viral Vector Purification Products Market for Adenoviral Vectors, 2020-2030 (USD Million)
Figure 11.15 Adenoviral Vector Purification Products Market: Distribution by Type of Purification Technique, 2020-2030 (USD Million)
Figure 11.16 Adenoviral Vector Purification Products Market: Distribution by Type of Therapy, 2020-2030 (USD Million)
Figure 11.17 Adenoviral Vector Purification Products Market: Distribution by Therapeutic Area, 2020-2030 (USD Million)
Figure 11.18 Adenoviral Vector Purification Products Market: Distribution by Scale of Operation, 2020-2030 (USD Million)
Figure 11.19 Adenoviral Vector Purification Products Market: Distribution by Geographical Location, 2020-2030 (USD Million)
Figure 11.20 Viral Vector Purification Products Market for Lentiviral Vectors, 2020-2030 (USD Million)
Figure 11.21 Lentiviral Vector Purification Products Market: Distribution by Type of Purification Technique, 2020-2030 (USD Million)
Figure 11.22 Lentiviral Vector Purification Products Market: Distribution by Type of Therapy, 2020-2030 (USD Million)
Figure 11.23 Lentiviral Vector Purification Products Market: Distribution by Therapeutic Area, 2020-2030 (USD Million)
Figure 11.24 Lentiviral Vector Purification Products Market: Distribution by Scale of Operation, 2020-2030 (USD Million)
Figure 11.25 Lentiviral Vector Purification Products Market: Distribution by Geographical Location, 2020-2030 (USD Million)
Figure 11.26 Viral Vector Purification Products Market for Retroviral Vectors, 2020-2030 (USD Million)
Figure 11.27 Retroviral Vector Purification Products Market: Distribution by Type of Purification Technique, 2020-2030 (USD Million)
Figure 11.28 Retroviral Vector Purification Products Market: Distribution by Type of Therapy, 2020-2030 (USD Million)
Figure 11.29 Retroviral Vector Purification Products Market: Distribution by Therapeutic Area, 2020-2030 (USD Million)
Figure 11.30 Retroviral Vector Purification Products Market: Distribution by Scale of Operation, 2020-2030 (USD Million)
Figure 11.31 Retroviral Vector Purification Products Market: Distribution by Geographical Location, 2020-2030 (USD Million)
Figure 11.32 Viral Vector Purification Products Market for Other Viral Vectors, 2020-2030 (USD Million)
Figure 11.33 Other Viral Vector Purification Products Market: Distribution by Type of Purification Technique, 2020-2030 (USD Million)
Figure 11.34 Other Viral Vector Purification Products Market: Distribution by Type of Therapy, 2020-2030 (USD Million)
Figure 11.35 Other Viral Vector Purification Products Market: Distribution by Therapeutic Area, 2020-2030 (USD Million)
Figure 11.36 Other Viral Vector Purification Products Market: Distribution by Scale of Operation, 2020-2030 (USD Million)
Figure 11.37 Other Viral Vector Purification Products Market: Distribution by Geographical Location, 2020-2030 (USD Million)

List Of Tables

Table 3.1 Key Comparison of Different Types of Viral Vectors
Table 4.1 List of Viral Vector Purification Products
Table 4.2 Viral Vector Purification Products for Chromatography: Additional Details
Table 4.3 Viral Vector Purification Products for Centrifugation: Additional Details
Table 4.4 Viral Vector Purification Products for Filtration: Additional Details
Table 4.5 List of Viral Vector Purification Products Developers
Table 5.1 Agilent Technologies: Company Snapshot
Table 5.2 Agilent Technologies: Recent Developments and Future Outlook
Table 5.3 BIA Separations: Company Snapshot
Table 5.4 BIA Separations: Recent Developments and Future Outlook
Table 5.5 Bio-Rad Laboratories: Company Snapshot
Table 5.6 Bio-Rad Laboratories: Recent Developments and Future Outlook
Table 5.7 BioVision: Company Snapshot
Table 5.8 BioVision: Recent Developments and Future Outlook
Table 5.9 Cytiva (formerly GE Lifesciences): Company Snapshot
Table 5.10 Cytiva (formerly GE Lifesciences): Recent Developments and Future Outlook
Table 5.11 Merck: Company Snapshot
Table 5.12 Merck: Recent Developments and Future Outlook
Table 5.13 Sartorius: Company Snapshot
Table 5.14 Sartorius: Recent Developments and Future Outlook
Table 5.15 Takara Bio: Company Snapshot
Table 5.16 Takara Bio: Recent Developments and Future Outlook
Table 5.17 Thermo Fisher Scientific: Company Snapshot
Table 5.18 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 6.1 AAV Vector-based Therapy Developers: Most Likely Partners
Table 6.2 AAV Vector-based Therapy Developers: Likely Partners
Table 6.3 AAV Vector-based Therapy Developers: Less Likely Partners
Table 6.4 AAV Vector-based Therapy Developers: Least Likely Partners
Table 6.5 Adenoviral Vector-based Therapy Developers: Most Likely Partners
Table 6.6 Adenoviral Vector-based Therapy Developers: Likely Partners
Table 6.7 Adenoviral Vector-based Therapy Developers: Less Likely Partners
Table 6.8 Adenoviral Vector-based Therapy Developers: Least Likely Partners
Table 6.9 Lentiviral Vector-based Therapy Developers: Most Likely Partners
Table 6.10 Lentiviral Vector-based Therapy Developers: Likely Partners
Table 6.11 Lentiviral Vector-based Therapy Developers: Less Likely Partners
Table 6.12 Lentiviral Vector-based Therapy Developers: Least Likely Partners
Table 6.13 Retroviral Vector-based Therapy Developers: Most Likely Partners
Table 6.14 Retroviral Vector-based Therapy Developers: Likely Partners
Table 6.15 Retroviral Vector-based Therapy Developers: Less Likely Partners
Table 6.16 Retroviral Vector-based Therapy Developers: Least Likely Partners
Table 6.17 Other Viral Vector-based Therapy Developers: Most Likely Partners
Table 6.18 Other Viral Vector-based Therapy Developers: Likely Partners
Table 6.19 Other Viral Vector-based Therapy Developers: Less Likely Partners
Table 6.20 Other Viral Vector-based Therapy Developers: Least Likely Partners
Table 6.21 AAV Vector Manufacturers: Most Likely Partners
Table 6.22 AAV Vector Manufacturers: Likely Partners
Table 6.23 AAV Vector Manufacturers: Less Likely Partners
Table 6.24 AAV Vector Manufacturers: Least Likely Partners
Table 6.25 Adenoviral Vector Manufacturers: Most Likely Partners
Table 6.26 Adenoviral Vector Manufacturers: Likely Partners
Table 6.27 Adenoviral Vector Manufacturers: Less Likely Partners
Table 6.28 Adenoviral Vector Manufacturers: Least Likely Partners
Table 6.29 Lentiviral Vector Manufacturers: Most Likely Partners
Table 6.30 Lentiviral Vector Manufacturers: Likely Partners
Table 6.31 Lentiviral Vector Manufacturers: Less Likely Partners
Table 6.32 Lentiviral Vector Manufacturers: Least Likely Partners
Table 6.33 Retroviral Vector Manufacturers: Most Likely Partners
Table 6.34 Retroviral Vector Manufacturers: Likely Partners
Table 6.35 Retroviral Vector Manufacturers: Less Likely Partners
Table 6.36 Retroviral Vector Manufacturers: Least Likely Partners
Table 6.37 Other Viral Vector Manufacturers: Most Likely Partners
Table 6.38 Other Viral Vector Manufacturers: Likely Partners
Table 6.39 Other Viral Vector Manufacturers: Less Likely Partners
Table 6.40 Other Viral Vector Manufacturers: Least Likely Partners
Table 9.1 List of TFF Products
Table 10.1 List of Commercial Scale Vector Manufacturers
Table 12.1 Concluding Remarks
Table 13.1 Virovek: Company Snapshot
Table 13.2 Vigene Biosciences: Company Snapshot
Table 13.3 Vibalogics: Company Snapshot
Table 14.1 Viral Vector Purification Products: Distribution by Type of Product
Table 14.2 Viral Vector Purification Products: Distribution by Type of Purification Technique
Table 14.3 Viral Vector Purification Products: Distribution by Scale of Operation
Table 14.4 Viral Vector Purification Products: Distribution by Type of Viral Vector
Table 14.5 Viral Vector Purification Products: Distribution by Type of Chromatographic Technique
Table 14.6 Viral Vector Purification Product Developers: Distribution by Year of Establishment
Table 14.7 Viral Vector Purification Product Developers: Distribution by Company Size
Table 14.8 Viral Vector Purification Product Developers: Distribution by Geographical Location
Table 14.9 Viral Vector based Therapies: Distribution by Trial Registration Year
Table 14.10 Viral Vector based Therapies: Distribution by Trial Phase
Table 14.11 Viral Vector based Therapies: Distribution by Trial Status
Table 14.12 Viral Vector based Therapies: Distribution by Type of Therapy
Table 14.13 Viral Vector based Therapies: Distribution by Therapeutic Area
Table 14.14 Viral Vector based Therapies: Distribution by Type of Sponsor / Collaborator
Table 14.15 Viral Vector based Therapies: Distribution by Geographical Location and Trial Status
Table 14.16 Viral Vector based Therapies: Most Active Players by Number of Registered Trials
Table 14.17 Viral Vector based Therapies: Distribution by Patients Enrolled and Trial Phase
Table 14.18 Viral Vector based Therapies: Distribution by Patients Enrolled and Type of Therapy
Table 14.19 Viral Vector based Therapies: Distribution by Patients Enrolled and Therapeutic Area
Table 14.20 Viral Vector based Therapies: Distribution by Patients Enrolled, Trial Status and Geographical Location
Table 14.21 AAV Vector based Therapies: Distribution by Trial Registration Year
Table 14.22 AAV Vector based Therapies: Distribution by Trial Phase
Table 14.23 AAV Vector based Therapies: Distribution by Trial Status
Table 14.24 AAV Vector based Therapies: Distribution by Type of Therapy
Table 14.25 AAV Vector based Therapies: Distribution by Therapeutic Area
Table 14.26 AAV Vector based Therapies: Distribution by Type of Sponsor / Collaborator
Table 14.27 AAV Vector based Therapies: Distribution by Geographical Location and Trial Status
Table 14.28 AAV Vector based Therapies: Most Active Players by Number of Registered Trials
Table 14.29 AAV Vector based Therapies: Distribution by Patients Enrolled and Trial Phase
Table 14.30 AAV Vector based Therapies: Distribution by Patients Enrolled and Type of Therapy
Table 14.31 AAV Vector based Therapies: Distribution by Patients Enrolled and Therapeutic Area
Table 14.32 AAV Vector based Therapies: Distribution by Patients Enrolled, Trial Status and Geographical Location
Table 14.33 Adenoviral Vector based Therapies: Distribution by Trial Registration Year
Table 14.34 Adenoviral Vector based Therapies: Distribution by Trial Phase
Table 14.35 Adenoviral Vector based Therapies: Distribution by Trial Status
Table 14.36 Adenoviral Vector based Therapies: Distribution by Type of Therapy
Table 14.37 Adenoviral Vector based Therapies: Distribution by Therapeutic Area
Table 14.38 Adenoviral Vector based Therapies: Distribution by Type of Sponsor / Collaborator
Table 14.39 Adenoviral Vector based Therapies: Distribution by Geographical Location and Trial Status
Table 14.40 Adenoviral Vector based Therapies: Most Active Players by Number of Registered Trials
Table 14.41 Adenoviral Vector based Therapies: Distribution by Patients Enrolled and Trial Phase
Table 14.42 Adenoviral Vector based Therapies: Distribution by Patients Enrolled and Type of Therapy
Table 14.43 Adenoviral Vector based Therapies: Distribution by Patients Enrolled and Therapeutic Area
Table 14.44 Adenoviral Vector based Therapies: Distribution by Patients Enrolled, Trial Status and Geographical Location
Table 14.45 Lentiviral Vector based Therapies: Distribution by Trial Registration Year
Table 14.46 Lentiviral Vector based Therapies: Distribution by Trial Phase
Table 14.47 Lentiviral Vector based Therapies: Distribution by Trial Status
Table 14.48 Lentiviral Vector based Therapies: Distribution by Type of Therapy
Table 14.49 Lentiviral Vector based Therapies: Distribution by Therapeutic Area
Table 14.50 Lentiviral Vector based Therapies: Distribution by Type of Sponsor / Collaborator
Table 14.51 Lentiviral Vector based Therapies: Distribution by Geographical Location
Table 14.52 Lentiviral Vector based Therapies: Most Active Players by Number of Registered Trials
Table 14.53 Lentiviral Vector based Therapies: Distribution by Patients Enrolled and Trial Phase
Table 14.54 Lentiviral Vector based Therapies: Distribution by Patients Enrolled and Type of Therapy
Table 14.55 Lentiviral Vector based Therapies: Distribution by Patients Enrolled and Therapeutic Area
Table 14.56 Lentiviral Vector based Therapies: Distribution by Patients Enrolled, Trial Status and Geographical Location
Table 14.57 Retroviral Vector based Therapies: Distribution by Trial Registration Year
Table 14.58 Retroviral Vector based Therapies: Distribution by Trial Phase
Table 14.59 Retroviral Vector based Therapies: Distribution by Trial Status
Table 14.60 Retroviral Vector based Therapies: Distribution by Type of Therapy
Table 14.61 Retroviral Vector based Therapies: Distribution by Therapeutic Area
Table 14.62 Retroviral Vector based Therapies: Distribution by Type of Sponsor / Collaborator
Table 14.63 Retroviral Vector based Therapies: Distribution by Geographical Location
Table 14.64 Retroviral Vector based Therapies: Most Active Players by Number of Registered Trials
Table 14.65 Retroviral Vector based Therapies: Distribution by Patients Enrolled and Trial Phase
Table 14.66 Retroviral Vector based Therapies: Distribution by Patients Enrolled and Type of Therapy
Table 14.67 Retroviral Vector based Therapies: Distribution by Patients Enrolled and Therapeutic Area
Table 14.68 Retroviral Vector based Therapies: Distribution by Patients Enrolled, Trial Status and Geographical Location
Table 14.69 Other Viral Vector based Therapies: Distribution by Trial Registration Year
Table 14.70 Other Viral Vector based Therapies: Distribution by Trial Phase
Table 14.71 Other Viral Vector based Therapies: Distribution by Trial Status
Table 14.72 Other Viral Vector based Therapies: Distribution by Type of Therapy
Table 14.73 Other Viral Vector based Therapies: Distribution by Therapeutic Area
Table 14.74 Other Viral Vector based Therapies: Distribution by Type of Sponsor / Collaborator
Table 14.75 Other Viral Vector based Therapies: Distribution by Geographical Location
Table 14.76 Other Viral Vector based Therapies: Most Active Players by Number of Registered Trials
Table 14.77 Other Viral Vector based Therapies: Distribution by Patients Enrolled and Trial Phase
Table 14.78 Other Viral Vector based Therapies: Distribution by Patients Enrolled and Type of Therapy
Table 14.79 Other Viral Vector based Therapies: Distribution by Patients Enrolled and Therapeutic Area
Table 14.80 Other Viral Vector based Therapies: Distribution by Patients Enrolled, Trial Status and Geographical Location
Table 14.81 Global Clinical Demand for Viral Vectors, 2020-2030 (Thousand Patients)
Table 14.82 Clinical Demand for Viral Vectors: Distribution by Type of Vector (Thousand Patients)
Table 14.83 Clinical Demand for Viral Vectors: Distribution by Type of Therapy (Thousand Patients)
Table 14.84 Clinical Demand for Viral Vectors: Distribution by Therapeutic Area (Thousand Patients)
Table 14.85 Clinical Demand for Viral Vectors: Distribution by Geographical Location (Thousand Patients)
Table 14.86 Global Commercial Demand for Viral Vectors, 2020-2030 (Thousand Patients)
Table 14.87 Commercial Demand for Viral Vectors: Distribution by Type of Vector (Thousand Patients)
Table 14.88 Commercial Demand for Viral Vectors: Distribution by Type of Therapy (Thousand Patients)
Table 14.89 Commercial Demand for Viral Vectors: Distribution by Therapeutic Area (Thousand Patients)
Table 14.90 Commercial Demand for Viral Vectors: Distribution by Geographical Location (Thousand Patients)
Table 14.91 Commercial Scale Viral Vector Manufacturers: Distribution by Year of Establishment
Table 14.92 Commercial Scale Viral Vector Manufacturers: Distribution by Company Size
Table 14.93 Commercial Scale Viral Vector Manufacturers: Distribution by Type of Viral Vector
Table 14.94 Commercial Scale Viral Vector Manufacturers: Distribution by Purpose of Production
Table 14.95 Commercial Scale Viral Vector Manufacturers: Distribution by Geographical Location
Table 14.96 Overall Viral Vector Purification Products Market, Conservative, Base and Optimistic Scenario, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.97 Viral Vector Purification Products Market: Distribution by Type of Viral Vector, Conservative, Base and Optimistic Scenario, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.98 Viral Vector Purification Products Market: Distribution by Type of Purification Technique, Conservative, Base and Optimistic Scenario, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.99 Viral Vector Purification Products Market: Distribution by Type of Therapy, Conservative, Base and Optimistic Scenario, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.100 Viral Vector Purification Products Market: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.101 Viral Vector Purification Products Market: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.102 Viral Vector Purification Products Market: Distribution by Geographical Location, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.103 Viral Vector Purification Products Market for AAV Vectors, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.104 AAV Vector Purification Products Market: Distribution by Type of Purification Technique, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.105 AAV Vector Purification Products Market: Distribution by Type of Therapy, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.106 AAV Vector Purification Products Market: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.107 AAV Vector Purification Products Market: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.108 AAV Vector Purification Products Market: Distribution by Geographical Location, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.109 Viral Vector Purification Products Market for Adenoviral Vectors, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.110 Adenoviral Vector Purification Products Market: Distribution by Type of Purification Technique, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.111 Adenoviral Vector Purification Products Market: Distribution by Type of Therapy, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.112 Adenoviral Vector Purification Products Market: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.113 Adenoviral Vector Purification Products Market: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.114 Adenoviral Vector Purification Products Market: Distribution by Geographical Location, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.115 Viral Vector Purification Products Market for Lentiviral Vectors, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.116 Lentiviral Vector Purification Products Market: Distribution by Type of Purification Technique, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.117 Lentiviral Vector Purification Products Market: Distribution by Type of Therapy, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.118 Lentiviral Vector Purification Products Market: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.119 Lentiviral Vector Purification Products Market: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.120 Lentiviral Vector Purification Products Market: Distribution by Geographical Location, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.121 Viral Vector Purification Products Market for Retroviral Vectors, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.122 Retroviral Vector Purification Products Market: Distribution by Type of Purification Technique, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.123 Retroviral Vector Purification Products Market: Distribution by Type of Therapy, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.124 Retroviral Vector Purification Products Market: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.125 Retroviral Vector Purification Products Market: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.126 Retroviral Vector Purification Products Market: Distribution by Geographical Location, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.127 Viral Vector Purification Products Market for Other Viral Vectors, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.128 Other Viral Vector Purification Products Market: Distribution by Type of Purification Technique, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.129 Other Viral Vector Purification Products Market: Distribution by Type of Therapy, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.130 Other Viral Vector Purification Products Market: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.131 Other Viral Vector Purification Products Market: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.132 Other Viral Vector Purification Products Market: Distribution by Geographical Location, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)

Listed Companies

The following companies and organizations have been mentioned in the report.

  1. 4D Molecular Therapeutics
  2. Abbott
  3. Abeona Therapeutics
  4. Actus Therapeutics
  5. Adaptimmune Therapeutics
  6. Addgene
  7. Advanced BioScience Laboratories
  8. Advantagene
  9. Advaxis
  10. Advent
  11. Adverum Biotechnologies
  12. Agilent Technologies
  13. Allergan
  14. Allife Medical Science and Technology
  15. Allogene Therapeutics
  16. AlphaVax
  17. ALSTEMlstem
  18. Altor BioScience
  19. American Gene Technologies
  20. Amgen
  21. Amicus Therapeutics
  22. AMSBIO
  23. Anaeropharma Science
  24. Angionetics
  25. apceth Biopharma
  26. Apic Bio
  27. Applied Biological Materials
  28. Applied Genetic Technologies Corporation
  29. Applied Viromics
  30. Arthrogen
  31. Aruvant Sciences
  32. Asklepios BioPharmaceutical
  33. Atara Biotherapeutics
  34. ATVIO Biotechnology
  35. Audentes Therapeutics
  36. Aurora Biopharma
  37. Autolus
  38. AVROBIO
  39. Axovant
  40. Batavia Biosciences
  41. Bayer
  42. Baylor College of Medicine 
  43. Beijing Biohealthcare Biotechnology
  44. Beijing Doing Biomedical
  45. Beijing Immunochina Medical Science & Technology
  46. Beijing Mario Biotech
  47. Beijing Sanwater Biological Technology
  48. Bellicum Pharmaceuticals
  49. BIA Separations
  50. Bioceltech Therapeutics
  51. Biogen
  52. BioMarin Pharmaceutical
  53. BioNTech Innovative Manufacturing Services
  54. Bio-Rad 
  55. BioReliance
  56. Bioverativ
  57. Biovian
  58. BioVision
  59. Blue Sky BioServices
  60. bluebird bio
  61. Brammer Bio
  62. Bristol-Myers Squibb
  63. Carina Biotech
  64. CARsgen Therapeutics
  65. Castle Creek Pharmaceuticals
  66. Celgene
  67. Cell Biolabs
  68. Cellectis
  69. CELLforCURE
  70. CellGenTech
  71. Cellular Biomedicine
  72. Celonic
  73. Celyad 
  74. Centre for Process Innovation
  75. CEVEC Pharmaceuticals 
  76. China Immunotech 
  77. Clean Cells
  78. Cobra Biologics
  79. Cold Genesys
  80. Creative Biogene
  81. Creative Biolabs
  82. CRISPR Therapeutics
  83. Cytiva
  84. Cytovance Biologics
  85. Daiichi Sankyo 
  86. DNAtrix
  87. Editas Medicine
  88. Emergent BioSolutions
  89. Epeius Biotechnologies
  90. Errant Gene Therapeutics
  91. Esteve
  92. ExcellGene
  93. Fibrocell
  94. FinVector
  95. FIT Biotech
  96. FKD Therapies
  97. Flash Therapeutics
  98. Flexion Therapeutics
  99. Formula Pharmaceuticals
  100. Fosun Pharma
  101. Freeline Therapeutics
  102. FUJIFILM Diosynth Biotechnologies
  103. GE Healthcare
  104. GEG Tech
  105. Gene Biotherapeutics  
  106. GeneCure Biotechnologies
  107. GeneDetect
  108. Genelux Corporation
  109. Genethon
  110. Genezen Laboratories
  111. GenIbet Biopharmaceuticals
  112. GenSight Biologics
  113. GenVec
  114. GlaxoSmithKline
  115. Gracell Biotechnologies
  116. Guangdong Xiangxue Precision Medical Technology
  117. Guangdong Zhaotai InVivo Biomedicine
  118. Guangzhou Anjie Biomedical Technology
  119. Guangzhou Double Bioproducts
  120. Guangzhou FineImmune Biotechnology
  121. Guangzhou YiYang Biological Technology
  122. Gyroscope Therapeutics
  123. Hebei Senlang Biotechnology
  124. Hemera Biosciences
  125. Henan Hualong Biotechnology Company 
  126. Herantis Pharma
  127. Holostem Terapie Avanzate
  128. Homology Medicines
  129. Horama
  130. Hrain Biotechnology
  131. Hunan Zhaotai Yongren Biotech
  132. Hunan Zhaotai Yongren Medical Innovation
  133. iCAR Bio Therapeutics 
  134. iCarTAB BioMed
  135. iCell Gene Therapeutics
  136. ID Pharma
  137. Immatics
  138. Immunocore
  139. Innovative Cellular Therapeutics
  140. Janssen Pharmaceuticals
  141. Juno Therapeutics
  142. JW Therapeutics
  143. KAEDI
  144. Kite Pharma
  145. Kolon TissueGene
  146. Krystal Biotech
  147. Kuur Therapeutics
  148. Lentigen Technology
  149. Leucid Bio
  150. Lion TCR 
  151. Lokon Pharma
  152. Lonza
  153. Lysogene
  154. Marino Biotechnology
  155. Marsala Biotech
  156. Mayflower Bioscience
  157. Medigene
  158. MedImmune
  159. MeiraGTx
  160. Merck
  161. Milo Biotechnology
  162. Miltenyi Biotec
  163. MingJu Therapeutics
  164. MolMed
  165. Momotaro-Gene
  166. MultiVir
  167. Mustang Bio
  168. Myonexus Therapeutics
  169. Nanjing Legend Biotech 
  170. NEC
  171. Neuralgene
  172. Neurocrine Biosciences
  173. Nightstar Therapeutics
  174. Nikon CeLL innovation
  175. Norgen Biotek
  176. Novartis
  177. Novasep
  178. Oncolys BioPharma
  179. ORCA Therapeutics
  180. Orchard Therapeutics
  181. Oxford BioMedica
  182. Oxford Genetics 
  183. OZ Biosciences 
  184. Pall Biotech
  185. Paragon Gene Therapy
  186. PeriphaGen
  187. PersonGen BioTherapeutics
  188. Pfizer
  189. Pinze Lifetechnology
  190. Precigen
  191. Precision BioSciences
  192. ProBioGen
  193. ProMab Biotechnologies
  194. PsiOxus Therapeutics
  195. PTC Therapeutics
  196. Regeneron Pharmaceuticals
  197. REGENXBIO
  198. ReiThera
  199. Renova Therapeutics
  200. Rocket Pharmaceuticals
  201. Rubius Therapeutics
  202. SAB Technology
  203. Sangamo Therapeutics
  204. Sanofi
  205. Sarepta Therapeutics
  206. Sartorius
  207. Servier
  208. Shanghai Bioray Laboratory
  209. Shanghai GeneChem
  210. Shanghai Longyao Biotechnology 
  211. Shanghai Sinobioway Sunterra Biotechnology
  212. Shanghai Sunway Biotech
  213. Shanghai Unicar-Therapy Bio-medicine Technology
  214. Shenzhen BinDeBio
  215. Shenzhen SiBiono GeneTech
  216. Shionogi
  217. SignaGen Laboratories
  218. SillaJen
  219. Sinobioway Cell Therapy
  220. SIRION Biotech
  221. Solid Biosciences
  222. Sorrento Therapeutics
  223. SOTIO
  224. Spark Therapeutics
  225. System Biosciences
  226. Takara Bio
  227. Takeda
  228. Targovax 
  229. Tasly Biopharmaceuticals
  230. TCR2 Therapeutics
  231. TCRCure Biopharma
  232. The Beijing Pregene Science and Technology
  233. The Pregene (ShenZhen) Biotechnology
  234. TheraBiologics
  235. Theravectys
  236. Thermo Fisher Scientific
  237. Tianjin Mycure Medical Technology
  238. Timmune
  239. Tmunity Therapeutics
  240. Tocagen
  241. Transgene
  242. Ultragenyx Pharmaceutical
  243. Union Stem Cell & Gene Engineering
  244. uniQure 
  245. Unum Therapeutics
  246. Vascular Biogenics
  247. VCN Biosciences
  248. Vector Biolabs
  249. Vertex Pharmaceuticals
  250. Vessl
  251. Vibalogics
  252. Vigene Biosciences
  253. ViralGEN
  254. Virapur
  255. ViraQuest
  256. Virovek
  257. Virttu Biologics
  258. VIVEbiotech
  259. Voyager Therapeutics
  260. Wuhan Sian Medical Technology
  261. WuXi AppTec
  262. Wyvern Pharmaceuticals
  263. Xiangxue Life Sciences
  264. Xiangxue Pharmaceutical
  265. XyloCor Therapeutics
  266. Yake Biotechnology
  267. Yposkesi
  268. Ziopharm Oncology

 

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com